[go: up one dir, main page]

JPS6480299A - Ligand and method for enhancing propagation of b-cells - Google Patents

Ligand and method for enhancing propagation of b-cells

Info

Publication number
JPS6480299A
JPS6480299A JP62146811A JP14681187A JPS6480299A JP S6480299 A JPS6480299 A JP S6480299A JP 62146811 A JP62146811 A JP 62146811A JP 14681187 A JP14681187 A JP 14681187A JP S6480299 A JPS6480299 A JP S6480299A
Authority
JP
Japan
Prior art keywords
ligand
cells
enhancing propagation
propagation
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP62146811A
Other languages
Japanese (ja)
Other versions
JPH0762040B2 (en
Inventor
Ei Retsudobetaa Jiefurii
Ei Kuraaku Edowaado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of JPS6480299A publication Critical patent/JPS6480299A/en
Publication of JPH0762040B2 publication Critical patent/JPH0762040B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP62146811A 1986-06-13 1987-06-12 Ligands and methods for enhancing B cell proliferation Expired - Lifetime JPH0762040B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13
US873884 1997-05-12

Publications (2)

Publication Number Publication Date
JPS6480299A true JPS6480299A (en) 1989-03-27
JPH0762040B2 JPH0762040B2 (en) 1995-07-05

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62146811A Expired - Lifetime JPH0762040B2 (en) 1986-06-13 1987-06-12 Ligands and methods for enhancing B cell proliferation

Country Status (22)

Country Link
JP (1) JPH0762040B2 (en)
KR (1) KR910004100B1 (en)
AT (1) AT398437B (en)
AU (1) AU617087B2 (en)
BE (1) BE1000587A4 (en)
CA (1) CA1338781C (en)
CH (1) CH676600A5 (en)
CY (1) CY1681A (en)
DE (1) DE3719398C2 (en)
DK (1) DK173940B1 (en)
FR (1) FR2607136B1 (en)
GB (1) GB2191494B (en)
GR (1) GR870930B (en)
HK (1) HK10293A (en)
IE (1) IE60486B1 (en)
IL (1) IL82841A (en)
IT (1) IT1208649B (en)
LU (1) LU86919A1 (en)
NL (1) NL195022C (en)
PT (1) PT85073B (en)
SE (1) SE504675C2 (en)
SG (1) SG118992G (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
RS50101B (en) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for immunomodulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959630A (en) * 1982-06-21 1984-04-05 デイナ−フア−バ−・キヤンサ−・インステイテユ−ト Monoclonal antibody against specific antigen
JPS59231025A (en) * 1983-02-24 1984-12-25 ロナルド ビリング Monoclonal antibody specific for monocytes and blast cells
JPS6069034A (en) * 1983-06-27 1985-04-19 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク Immunotoxins, agents containing immunotoxins, and methods for in vitro use of immunotoxins
JPS60214799A (en) * 1983-12-14 1985-10-28 ダナ−フア−バ−・キヤンサ−・インステイテユ−ト・インコ−ポレイテツド Monoclonal antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959630A (en) * 1982-06-21 1984-04-05 デイナ−フア−バ−・キヤンサ−・インステイテユ−ト Monoclonal antibody against specific antigen
JPS59231025A (en) * 1983-02-24 1984-12-25 ロナルド ビリング Monoclonal antibody specific for monocytes and blast cells
JPS6069034A (en) * 1983-06-27 1985-04-19 サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク Immunotoxins, agents containing immunotoxins, and methods for in vitro use of immunotoxins
JPS60214799A (en) * 1983-12-14 1985-10-28 ダナ−フア−バ−・キヤンサ−・インステイテユ−ト・インコ−ポレイテツド Monoclonal antibody

Also Published As

Publication number Publication date
KR880000582A (en) 1988-03-28
SE8702463L (en) 1987-12-14
CH676600A5 (en) 1991-02-15
SE8702463D0 (en) 1987-06-12
AU617087B2 (en) 1991-11-21
DE3719398A1 (en) 1988-01-28
DK173940B1 (en) 2002-03-04
PT85073A (en) 1987-07-01
CY1681A (en) 1993-10-10
DK302287D0 (en) 1987-06-12
IL82841A (en) 1992-11-15
LU86919A1 (en) 1989-03-08
JPH0762040B2 (en) 1995-07-05
KR910004100B1 (en) 1991-06-22
GB2191494A (en) 1987-12-16
CA1338781C (en) 1996-12-10
FR2607136A1 (en) 1988-05-27
AU7421487A (en) 1987-12-17
AT398437B (en) 1994-12-27
SE504675C2 (en) 1997-04-07
BE1000587A4 (en) 1989-02-14
NL195022C (en) 2003-06-18
PT85073B (en) 1990-07-31
GR870930B (en) 1987-12-16
ATA151387A (en) 1994-04-15
DK302287A (en) 1987-12-14
IE871563L (en) 1987-12-13
HK10293A (en) 1993-02-19
IT1208649B (en) 1989-07-10
GB2191494B (en) 1990-08-22
FR2607136B1 (en) 1989-09-15
DE3719398C2 (en) 1996-03-28
IE60486B1 (en) 1994-07-27
SG118992G (en) 1993-01-29
IL82841A0 (en) 1987-12-20
GB8713650D0 (en) 1987-07-15
NL8701371A (en) 1988-01-04
IT8720899A0 (en) 1987-06-12

Similar Documents

Publication Publication Date Title
EP0256965A3 (en) Method of and means for hydrodynamic mixing
ZA874482B (en) Method of chain combination
GB2190194B (en) Method for determination of antigen
ZA879331B (en) Method for preparation of mercaptobenzoates
JPS6480299A (en) Ligand and method for enhancing propagation of b-cells
PL264722A1 (en) Method of obtaining alkylsulfony-alkyl-chlorobenzenes
GB2195918B (en) Method for preventing fogging of surfaces
GB2146016B (en) Method for the preparation of haloacetals and halodioxolanes
AR243500A1 (en) Method for preparation of mercaptobenzoates
BG41264A1 (en) Method for determining of analgin and amidophen
CS70486A1 (en) Method of parallel quantitative determination of by-products in tetrabromodiade
IL79787A (en) Method and arrangement for notching gemstones
CS821986A1 (en) Method of preparation of chestnut-extract
BG42582A1 (en) Reagent and method for preparing of amidophosphites
BG43924A1 (en) N- derivative of cytazine and method for its preparation
RU1381883C (en) Method of determining optimal time of agglomeration
BG41428A1 (en) Method for study of thrombogeneity of biopreparations
SU1428374A1 (en) Method of iridoprosthesis
PL262333A1 (en) Method of obtaining -damascone
PL264891A1 (en) Method of preventing surface diffusion at structure-soilin-terface
PL263247A2 (en) Method of obtaining duroquinone
BG42579A1 (en) Method for preparing of c below 6- alkenes and c below 6- epoxy- compounds
BG45824A1 (en) Method for quantitative determination of cimethidine
CS7086A1 (en) Method of magnetographical checking
CS525386A1 (en) Method for photometric determination of hemoglobine

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term